Proteogenomics of Breast Cancer
NCI's Center for Cancer Research (CCR) Grand Rounds
Dr. Matthew Ellis ’ s clinical and basic research focuses on breast cancer. He has developed neoadjuvant endocrine therapy as an alternative to chemotherapy for promoting breast-conserving therapy in postmenopausal women with ER+ HER2- stage 2 and 3 disease. He developed and validated the Ki67 proliferation marker-based Preoperative Endocrine Prognostic Index which is now undergoing a large validation study (the ALTERNATE study). These clinical studies have provided the clinical context and tumor specimens for seminal investigations into the ER+ breast cancer somatic ge...
Source: Videocast - All Events - January 30, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Kimberly L. Blackwell, MD - Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting
Raising the Bar in HER2-Positive Breast Cancer: Improving Patient Outcomes in the Neoadjuvant Setting (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - August 10, 2016 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Edith A. Perez, MD - The "Golden Age" of HER2-Targeted Therapy for Breast Cancer: Translating Evidence to Practice to Improve Outcomes in Early-Stage and Advanced HER2-Positive Disease
The "Golden Age" of HER2-Targeted Therapy for Breast Cancer: Translating Evidence to Practice to Improve Outcomes in Early-Stage and Advanced HER2-Positive Disease (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - September 2, 2014 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
